Developer docs
API playgroundTry for free, no card

Search company profiles

Genethon

Full company profile

uuid003w65u

Namestring
Genethon
Legal namestring
Généthon
Websiteurl
genethon.fr
Company typeenum
Private
Founded yearint
1990
Descriptiontext

Genethon is a French nonprofit biotech founded in 1990 by the patient organization AFM-Téléthon, dedicated to developing gene therapies for rare genetic diseases that are commercially unattractive to for-profit pharmaceutical companies. The organization operates a 15-candidate pipeline spanning neuromuscular diseases (Duchenne muscular dystrophy, limb-girdle muscular dystrophies, myotubular myopathy, SMA), liver metabolic disorders (Crigler-Najjar syndrome, Pompe disease, GSD1a, Cori disease), blood disorders (sickle cell disease, Fanconi anemia), and immune deficiencies (Wiskott-Aldrich syndrome, SCID, chronic septic granulomatosis).

Its core technology stack centers on AAV gene therapy vectors (notably AAV8 for GNT0004 in DMD), CRISPR/Cas9 gene editing (including a mutation-independent utrophin upregulation approach for DMD), microdystrophin transgenes with muscle-specific promoters, lentiviral vectors with embedded microRNAs, and dual-AAV split-intein approaches. Genethon complements these with proprietary platform capabilities including AI-powered AAV capsid engineering via its Ampersand Biomedicines partnership, cardiotoxicity mitigation strategies for high-dose AAV, imlifidase pretreatment to overcome AAV seropositivity (applicable to ~1 in 3 patients), and an ISO 20387-certified DNA Bank. Clinical-stage lead asset GNT0004 has demonstrated +9 NSAA points, 173m improvement in 6-minute walk test, and 70% sustained CPK reduction at 2 years at a notably low therapeutic dose of 3×10¹³ vg/kg.

Genethon's revenue model is hybrid and nonprofit: ~€800 million in cumulative AFM-Téléthon funding since 1990 supports R&D operations, complemented by licensing royalties (e.g., GAA transgene to AskBio), patent licensing to biotech companies, and research services leveraging its DNA bank and imaging cytometry platform. Distribution occurs exclusively through academic clinical trial sites in France, the UK, and the US, with eventual commercialization routed through spin-off Atamyo Therapeutics and the GenoTher biocluster. The organization employs 200+ R&D staff at its Évry-Courcouronnes headquarters within the Genopole biocluster and is led by CEO Frédéric Revah (since 2010) under President Laurence Tiennot-Herment.

Short descriptiontext

Genethon is a French nonprofit biotech founded in 1990 by AFM-Téléthon that develops AAV, CRISPR, and lentiviral gene therapies for ultra-rare genetic diseases, with 15 candidates in its pipeline and lead program GNT0004 in Phase III for Duchenne muscular dystrophy.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
251–500
akta.pro rankint
HeadquartersÉvry, France
HQ citystring
Évry
HQ countrystring
France
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
gene therapy research, rare disease therapeutics, AAV vector development, nonprofit biotech, CRISPR gene editing
Industry5 codes
PRIMARYHLAAACAE
Gene Therapy for Rare/Monogenic Diseases
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAACAN
Gene Therapy CMC/Process Development Platforms (capsid engineering, producer cell lines, plasmids, upstream/downstream)
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAACAD
Genome Editing Gene Therapies (CRISPR/TALEN/ZFN; in vivo/ex vivo)
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAACAH
Neurology/CNS Gene Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAGADAF
Molecular & Genetic Testing (PCR/NGS/qPCR)
NAICS code3 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
  • Medical Laboratories621511
SIC code3 codes
  • Services-Commercial Physical & Biological Research8731
  • Services-Medical Laboratories8071
  • Biological Products, (No Disgnostic Substances)2836
Product category
Gene Therapy / Rare Disease Biopharmaceuticals
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Nonprofit Research Funding and Charitable Donations
TypeSubscription Recurring
Description

Genethon is a French nonprofit biotech funded primarily by patient organization AFM-Téléthon, which has provided nearly €800m in funding since Genethon's founding in 1990. The nonprofit structure enables greater scientific and strategic risk-taking for rare diseases commercially unattractive to for-profit pharmaceutical companies. Revenue comes from grants, donations, and potentially future therapeutic product revenues upon regulatory approval.

pharmaceutical-technology.com
2Licensing Royalties and Technology Transfer
TypeLicensing Royalties
Description

Genethon licenses its proprietary technologies and gene therapy components to commercial partners. In January 2026, it concluded an exclusive worldwide licensing agreement with AskBio (a Bayer subsidiary) for a GAA transgene for Pompe disease treatment, and holds patents licensed to biotechnology companies.

genethon.fr
3Gene Therapy Clinical Development Services
TypeProfessional Services
Description

Through its partnership with academic medical centers, Genethon conducts clinical trials as the trial sponsor, with costs covered by its nonprofit funding model. The organization may also provide research services and access to its DNA bank and imaging cytometry platforms to external academic and industrial users.

genethon.fr
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Personnel, Infrastructure, Operations, Marketing or Sales, Supply Chain
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Genethon is a nonprofit French biotech research laboratory that develops gene therapies for rare genetic diseases, leveraging AAV vectors, CRISPR/Cas9 gene editing, and lentiviral platforms. It operates a pipeline of 15 gene therapy candidates covering Duchenne muscular dystrophy, Crigler-Najjar syndrome, limb-girdle muscular dystrophies, sickle cell disease, and other monogenic conditions, with its lead candidate GNT0004 in pivotal Phase III clinical trials. The organization also provides certified DNA banking, imaging cytometry services, and licenses proprietary gene therapy technologies to commercial partners.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 7 values shown
  • +9 NSAA points at 2 years vs untreated controls in DMD patients treated with GNT0004 at therapeutic dose (3×10¹³ vg/kg)
+6 more records
Product overview1 text field

Genethon is a nonprofit French biotech specializing in gene therapy research and development for rare genetic diseases. The organization operates as a research laboratory developing multiple clinical-stage gene therapy candidates, with GNT0004 for Duchenne muscular dystrophy being the most advanced (pivotal Phase III). The pipeline includes 15 gene therapy candidates across diverse rare diseases. Genethon also provides research platforms including a certified DNA Bank and Imaging Cytometry Platform. The organization leverages AAV vector technology, CRISPR gene editing, and collaborates with partners for bioproduction and clinical development.

Product and service7 records
1GNT0004
CategoryClinical-stage gene therapy candidate
Description

AAV8-based microdystrophin gene therapy for Duchenne muscular dystrophy, administered as a single intravenous injection at therapeutic dose of 3×10¹³ vg/kg. Currently in pivotal Phase III clinical trials in Europe (France, UK).

2GNT0003
CategoryClinical-stage gene therapy candidate
Description

Gene therapy for Crigler-Najjar syndrome using AAV8 vector, developed with imlifidase pretreatment approach to enable administration in patients with pre-existing AAV antibodies.

3ATA-200
CategoryClinical-stage gene therapy candidate
Description

Gene therapy for LGMD-R5 (limb-girdle muscular dystrophy type R5/sarcoglycanopathy), being developed in partnership with Atamyo Therapeutics, with clinical trial sites including the University of Florida Powell Gene Therapy Center.

4Gene Therapy Pipeline (15 candidates)
CategoryPipeline portfolio
Description

Portfolio of 15 gene therapy candidates for rare diseases covering Duchenne muscular dystrophy, Spinal muscular atrophy, SMA-PME and Farber's disease, Myotubular myopathy, Limb girdle muscular dystrophies, Wiskott-Aldrich syndrome, Fanconi's anemia, Sickle cell disease, Chronic septic granulomatosis, SCID, Cori Forbes disease, GSD1a, Crigler-Najjar syndrome, Pompe disease, and Leber Hereditary Optic Neuropathy.

5DNA Bank
CategoryBiobanking service platform
Description

European leading DNA and cell bank for genetic diseases, ISO 20387 certified, providing high-quality biological samples and services to the scientific and medical community.

6Imaging Cytometry Platform (ImCy)
CategoryTechnology service platform
Description

High-technology platform providing imaging and flow cytometry support for Genethon research, labeled by Génopole, also open to external users.

7DREPAMIR Clinical Trial (sickle cell disease gene therapy)
CategoryClinical-stage gene therapy
Description

Phase I/II clinical trial for sickle cell disease using an innovative bifunctional lentiviral vector developed by Mario Amendola's team at Genethon, conducted in collaboration with Institut Imagine, AP-HP, Inserm, and Université Paris Cité.

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership13 partners
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2026-05-21
Description

Exclusive collaboration to engineer new AAV vectors with enhanced tissue specificity for gene therapy, leveraging Ampersand's AI-powered Address, Navigate, Determine (AND) platform and Genethon's AAV expertise. Initially focused on skeletal muscle targeting with plans to expand to other tissues. Combines precision targeting technology with gene therapy development to improve therapeutic outcomes and reduce required doses.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-03-27
Description

Collaboration led by Prof. Marina Cavazzana and Dr. Anne Galy with Mario Amendola's team at Genethon contributing the bifunctional lentiviral vector for the DREPAMIR sickle cell disease clinical trial (Phase I/II). ANSM authorized the trial in March 2026.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2026-02-03
Description

Partnership extension with The Dion Foundation supporting the ATA-200 gene therapy program for LGMD-R5 limb-girdle muscular dystrophy. First three children treated in ongoing clinical trial; 90%+ muscle fiber expression of therapeutic SGCG protein demonstrated.

Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2026-01-14
Description

Exclusive worldwide licensing agreement for Genethon's proprietary GAA transgene for Pompe disease gene therapy. AskBio plans to initiate clinical trial in early 2026. Genethon's Immunology and Liver Diseases team developed and demonstrated preclinical efficacy of the therapy.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-10-10
Description

Collaboration on the GNT-018-IDES clinical trial testing imlifidase (IgG-degrading enzyme) as pretreatment to enable gene therapy in Crigler-Najjar syndrome patients with natural AAV immunity. Successfully demonstrated feasibility and safety, with bilirubin reduction enabling discontinuation of phototherapy 16 weeks post-injection in first patient.

6GenoTher Biocluster
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-05-15
Description

Co-founder of GenoTher, a France 2030-labeled biocluster exclusively dedicated to gene therapy. Partners include Genethon, Genopole, AP-HP, INSERM, University of Evry Paris-Saclay, Spark Therapeutics, and Yposkesi. Aims to structure, accelerate, and industrialize gene therapy innovation from research to commercialization.

genethon.fr
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Clinical trial site for ATA-200 LGMD-R5 gene therapy Phase 1b/2 study; Dr. Barry Byrne presented preliminary safety and efficacy data at ASGCT 2026.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Genethon operates its main research unit (UMR_S951 Integrare) as a joint unit with INSERM and University of Evry Paris-Saclay. Multiple collaborative research programs and co-authored publications.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Collaborative development of GNT0004 microdystrophin gene therapy for Duchenne muscular dystrophy, including preclinical research and transgene optimization.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Partnership with the Institute of Myology for DMD gene therapy development, immunology center creation (led by Klaudia Kuranda), and clinical trial execution. Both organizations are part of the AFM-Téléthon ecosystem.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Part of the Biotherapies Institute for Rare Diseases (Institut des biothérapies des maladies rares) created by AFM-Téléthon, alongside Genethon, Institute of Myology, and I-Stem (stem cell research center).

12Yposkesi (CDMO)
Strategic tierMinorTypeImplementation/ SI/ Consulting Partner
Description

Yposkesi is a CDMO (Contract Development and Manufacturing Organization) spin-off of Genethon, specialized in gene therapy manufacturing. Frédéric Revah serves on its Board.

genethon.fr
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Atamyo is a biotech spin-off of Genethon dedicated to neuromuscular gene therapies. Frédéric Revah serves as President of Atamyo's Strategic Committee. Collaboration on limb-girdle muscular dystrophy programs including ATA-200.

Recent move10 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Rare-disease biotech with AAV gene therapy (Roctavian for hemophilia A) and broad rare-disease portfolio. Comparable in AAV modality and rare-disease commercial positioning.

TypeBroad incumbent
Description

Novartis's gene therapy unit commercializing Zolgensma (onasemnogene abeparvovec) for spinal muscular atrophy — a neuromuscular AAV gene therapy directly comparable to Genethon's neuromuscular pipeline focus.

3Yposkesi
TypeOthers
Description

CDMO spin-off of Genethon specialized in gene therapy manufacturing. Comparable as the bioproduction backbone serving Genethon's pipeline and external gene therapy clients.

TypeDirect peer
Description

AAV-based gene therapy developer (Luxturna) now a Roche subsidiary and co-founder of the GenoTher biocluster with Genethon. Directly comparable as an AAV gene therapy company targeting rare monogenic diseases.

TypeBroad incumbent
Description

Global pharma with approved DMD gene therapy Beqvez (fordadistrogene movaparvovec). Comparable as a competing developer of AAV microdystrophin therapies for DMD and a major participant in rare-disease gene therapy.

6Bluebird Bio
TypeDirect peer
Description

Gene therapy company developing lentiviral vector therapies for rare genetic diseases (sickle cell, beta-thalassemia, cerebral adrenoleukodystrophy). Comparable modality and rare-disease focus to Genethon's lentiviral and AAV programs.

TypeDirect peer
Description

AAV gene therapy developer and Bayer subsidiary — Genethon's licensing partner for the Pompe disease GAA transgene. Comparable in AAV modality and rare-disease pipeline focus.

TypeEmerging player
Description

Biotech spin-off from Genethon focused on gene therapy for limb-girdle muscular dystrophies (ATA-200, ATA-100). Comparable as a clinical-stage AAV gene therapy company operating inside the AFM-Téléthon ecosystem.

TypeDirect peer
Description

Approved Elevidys (delandistrogene moxeparvovec) for Duchenne muscular dystrophy — the most direct competitor to Genethon's GNT0004 in the AAV microdystrophin space, with shared indication and modality.

TypeDirect peer
Description

AAV gene therapy company targeting rare diseases (hemophilia B with etranacogene dezaparvovec). Comparable to Genethon in modality, rare-disease focus, and European clinical pipeline.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles12 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Genethon

Gene Therapy / Rare Disease Biopharmaceuticalsgenethon.fr

Genethon is a French nonprofit biotech founded in 1990 by AFM-Téléthon that develops AAV, CRISPR, and lentiviral gene therapies for ultra-rare genetic diseases, with 15 candidates in its pipeline and lead program GNT0004 in Phase III for Duchenne muscular dystrophy.

What Genethon does

Genethon is a French nonprofit biotech founded in 1990 by the patient organization AFM-Téléthon, dedicated to developing gene therapies for rare genetic diseases that are commercially unattractive to for-profit pharmaceutical companies. The organization operates a 15-candidate pipeline spanning neuromuscular diseases (Duchenne muscular dystrophy, limb-girdle muscular dystrophies, myotubular myopathy, SMA), liver metabolic disorders (Crigler-Najjar syndrome, Pompe disease, GSD1a, Cori disease), blood disorders (sickle cell disease, Fanconi anemia), and immune deficiencies (Wiskott-Aldrich syndrome, SCID, chronic septic granulomatosis).

Its core technology stack centers on AAV gene therapy vectors (notably AAV8 for GNT0004 in DMD), CRISPR/Cas9 gene editing (including a mutation-independent utrophin upregulation approach for DMD), microdystrophin transgenes with muscle-specific promoters, lentiviral vectors with embedded microRNAs, and dual-AAV split-intein approaches. Genethon complements these with proprietary platform capabilities including AI-powered AAV capsid engineering via its Ampersand Biomedicines partnership, cardiotoxicity mitigation strategies for high-dose AAV, imlifidase pretreatment to overcome AAV seropositivity (applicable to ~1 in 3 patients), and an ISO 20387-certified DNA Bank. Clinical-stage lead asset GNT0004 has demonstrated +9 NSAA points, 173m improvement in 6-minute walk test, and 70% sustained CPK reduction at 2 years at a notably low therapeutic dose of 3×10¹³ vg/kg.

Genethon's revenue model is hybrid and nonprofit: ~€800 million in cumulative AFM-Téléthon funding since 1990 supports R&D operations, complemented by licensing royalties (e.g., GAA transgene to AskBio), patent licensing to biotech companies, and research services leveraging its DNA bank and imaging cytometry platform. Distribution occurs exclusively through academic clinical trial sites in France, the UK, and the US, with eventual commercialization routed through spin-off Atamyo Therapeutics and the GenoTher biocluster. The organization employs 200+ R&D staff at its Évry-Courcouronnes headquarters within the Genopole biocluster and is led by CEO Frédéric Revah (since 2010) under President Laurence Tiennot-Herment.

Genethon firmographics

Firmographics
Name
Genethon
Legal name
Généthon
Website
https://genethon.fr
Company type
Private
Founded year
1990
Operating status
Operating
Headcount range
251–500 employees
Short description
Genethon is a French nonprofit biotech founded in 1990 by AFM-Téléthon that develops AAV, CRISPR, and lentiviral gene therapies for ultra-rare genetic diseases, with 15 candidates in its pipeline and lead program GNT0004 in Phase III for Duchenne muscular dystrophy.
Ownership category
akta.pro rank

Genethon industry classification

Industry
Product category
Gene Therapy / Rare Disease Biopharmaceuticals
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417), Medical Laboratories (621511)
SIC
Services-Commercial Physical & Biological Research (8731), Services-Medical Laboratories (8071), Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAACAE
Gene Therapy for Rare/Monogenic Diseases
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAACAN
Gene Therapy CMC/Process Development Platforms (capsid engineering, producer cell lines, plasmids, upstream/downstream)
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAACAD
Genome Editing Gene Therapies (CRISPR/TALEN/ZFN; in vivo/ex vivo)
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAACAH
Neurology/CNS Gene Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAGADAF
Molecular & Genetic Testing (PCR/NGS/qPCR)

Keywords

  • Gene therapy research
  • Rare disease therapeutics
  • AAV vector development
  • Nonprofit biotech
  • CRISPR gene editing

Where Genethon is headquartered

Location

Headquarters

HQ city
Évry
HQ country
France
HQ region
Europe

Offices2 records

Markets served

Genethon business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Technology or R&D, Personnel, Infrastructure, Operations, Marketing or Sales, Supply Chain

Revenue model

  1. Nonprofit Research Funding and Charitable Donations: Genethon is a French nonprofit biotech funded primarily by patient organization AFM-Téléthon, which has provided nearly €800m in funding since Genethon's founding in 1990. The nonprofit structure enables greater scientific and strategic risk-taking for rare diseases commercially unattractive to for-profit pharmaceutical companies. Revenue comes from grants, donations, and potentially future therapeutic product revenues upon regulatory approval.
  2. Licensing Royalties and Technology Transfer: Genethon licenses its proprietary technologies and gene therapy components to commercial partners. In January 2026, it concluded an exclusive worldwide licensing agreement with AskBio (a Bayer subsidiary) for a GAA transgene for Pompe disease treatment, and holds patents licensed to biotechnology companies.
  3. Gene Therapy Clinical Development Services: Through its partnership with academic medical centers, Genethon conducts clinical trials as the trial sponsor, with costs covered by its nonprofit funding model. The organization may also provide research services and access to its DNA bank and imaging cytometry platforms to external academic and industrial users.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Genethon product offering

Product offering

Core offering

Genethon is a nonprofit French biotech research laboratory that develops gene therapies for rare genetic diseases, leveraging AAV vectors, CRISPR/Cas9 gene editing, and lentiviral platforms. It operates a pipeline of 15 gene therapy candidates covering Duchenne muscular dystrophy, Crigler-Najjar syndrome, limb-girdle muscular dystrophies, sickle cell disease, and other monogenic conditions, with its lead candidate GNT0004 in pivotal Phase III clinical trials. The organization also provides certified DNA banking, imaging cytometry services, and licenses proprietary gene therapy technologies to commercial partners.

Product overview

Genethon is a nonprofit French biotech specializing in gene therapy research and development for rare genetic diseases. The organization operates as a research laboratory developing multiple clinical-stage gene therapy candidates, with GNT0004 for Duchenne muscular dystrophy being the most advanced (pivotal Phase III). The pipeline includes 15 gene therapy candidates across diverse rare diseases. Genethon also provides research platforms including a certified DNA Bank and Imaging Cytometry Platform. The organization leverages AAV vector technology, CRISPR gene editing, and collaborates with partners for bioproduction and clinical development.

Differentiator

Problem solved

Functional benefit

Products and services

  • GNT0004 AAV8-based microdystrophin gene therapy for Duchenne muscular dystrophy, administered as a single intravenous injection at therapeutic dose of 3×10¹³ vg/kg. Currently in pivotal Phase III clinical trials in Europe (France, UK).
  • GNT0003 Gene therapy for Crigler-Najjar syndrome using AAV8 vector, developed with imlifidase pretreatment approach to enable administration in patients with pre-existing AAV antibodies.
  • ATA-200 Gene therapy for LGMD-R5 (limb-girdle muscular dystrophy type R5/sarcoglycanopathy), being developed in partnership with Atamyo Therapeutics, with clinical trial sites including the University of Florida Powell Gene Therapy Center.
  • Gene Therapy Pipeline (15 candidates) Portfolio of 15 gene therapy candidates for rare diseases covering Duchenne muscular dystrophy, Spinal muscular atrophy, SMA-PME and Farber's disease, Myotubular myopathy, Limb girdle muscular dystrophies, Wiskott-Aldrich syndrome, Fanconi's anemia, Sickle cell disease, Chronic septic granulomatosis, SCID, Cori Forbes disease, GSD1a, Crigler-Najjar syndrome, Pompe disease, and Leber Hereditary Optic Neuropathy.
  • DNA Bank European leading DNA and cell bank for genetic diseases, ISO 20387 certified, providing high-quality biological samples and services to the scientific and medical community.
  • Imaging Cytometry Platform (ImCy) High-technology platform providing imaging and flow cytometry support for Genethon research, labeled by Génopole, also open to external users.
  • DREPAMIR Clinical Trial (sickle cell disease gene therapy) Phase I/II clinical trial for sickle cell disease using an innovative bifunctional lentiviral vector developed by Mario Amendola's team at Genethon, conducted in collaboration with Institut Imagine, AP-HP, Inserm, and Université Paris Cité.

Quantifiable outcome

  • +9 NSAA points at 2 years vs untreated controls in DMD patients treated with GNT0004 at therapeutic dose (3×10¹³ vg/kg)
  • +6 more outcomes

Companies that use Genethon

Customer profile

Named customers1 record

Segments2 records

Ideal customer profiles3 records

Genethon technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature6 records

Genethon partnerships and signals

Strategic signal

Partnerships

13 partnerships are on record, tiered core and minor.

  • Ampersand BiomedicinescoreTechnology or Integration · 21 May 2026Exclusive collaboration to engineer new AAV vectors with enhanced tissue specificity for gene therapy, leveraging Ampersand's AI-powered Address, Navigate, Determine (AND) platform and Genethon's AAV expertise. Initially focused on skeletal muscle targeting with plans to expand to other tissues. Combines precision targeting technology with gene therapy development to improve therapeutic outcomes and reduce required doses.
  • Institut Imagine / AP-HP / Inserm / Université Paris CitécoreStrategic or Co-development Partner · 27 March 2026Collaboration led by Prof. Marina Cavazzana and Dr. Anne Galy with Mario Amendola's team at Genethon contributing the bifunctional lentiviral vector for the DREPAMIR sickle cell disease clinical trial (Phase I/II). ANSM authorized the trial in March 2026.
  • The Dion FoundationminorStrategic or Co-development Partner · 3 February 2026Partnership extension with The Dion Foundation supporting the ATA-200 gene therapy program for LGMD-R5 limb-girdle muscular dystrophy. First three children treated in ongoing clinical trial; 90%+ muscle fiber expression of therapeutic SGCG protein demonstrated.
  • AskBio (Bayer AG subsidiary)coreOEM/ Whitelabel/ Licensing Partner · 14 January 2026Exclusive worldwide licensing agreement for Genethon's proprietary GAA transgene for Pompe disease gene therapy. AskBio plans to initiate clinical trial in early 2026. Genethon's Immunology and Liver Diseases team developed and demonstrated preclinical efficacy of the therapy.
  • Hansa BiopharmacoreStrategic or Co-development Partner · 10 October 2025Collaboration on the GNT-018-IDES clinical trial testing imlifidase (IgG-degrading enzyme) as pretreatment to enable gene therapy in Crigler-Najjar syndrome patients with natural AAV immunity. Successfully demonstrated feasibility and safety, with bilirubin reduction enabling discontinuation of phototherapy 16 weeks post-injection in first patient.
  • GenoTher BioclustercoreStrategic or Co-development Partner · 15 May 2025Co-founder of GenoTher, a France 2030-labeled biocluster exclusively dedicated to gene therapy. Partners include Genethon, Genopole, AP-HP, INSERM, University of Evry Paris-Saclay, Spark Therapeutics, and Yposkesi. Aims to structure, accelerate, and industrialize gene therapy innovation from research to commercialization.
  • University of Florida Powell Gene Therapy CenterminorStrategic or Co-development PartnerClinical trial site for ATA-200 LGMD-R5 gene therapy Phase 1b/2 study; Dr. Barry Byrne presented preliminary safety and efficacy data at ASGCT 2026.
  • INSERMcoreStrategic or Co-development PartnerGenethon operates its main research unit (UMR_S951 Integrare) as a joint unit with INSERM and University of Evry Paris-Saclay. Multiple collaborative research programs and co-authored publications.
  • University of London, Royal Holloway (Pr Dickson)coreStrategic or Co-development PartnerCollaborative development of GNT0004 microdystrophin gene therapy for Duchenne muscular dystrophy, including preclinical research and transgene optimization.
  • Institute of Myology (Paris)coreStrategic or Co-development PartnerPartnership with the Institute of Myology for DMD gene therapy development, immunology center creation (led by Klaudia Kuranda), and clinical trial execution. Both organizations are part of the AFM-Téléthon ecosystem.
  • I-StemminorStrategic or Co-development PartnerPart of the Biotherapies Institute for Rare Diseases (Institut des biothérapies des maladies rares) created by AFM-Téléthon, alongside Genethon, Institute of Myology, and I-Stem (stem cell research center).
  • Yposkesi (CDMO)minorImplementation/ SI/ Consulting PartnerYposkesi is a CDMO (Contract Development and Manufacturing Organization) spin-off of Genethon, specialized in gene therapy manufacturing. Frédéric Revah serves on its Board.
  • Atamyo TherapeuticsminorStrategic or Co-development PartnerAtamyo is a biotech spin-off of Genethon dedicated to neuromuscular gene therapies. Frédéric Revah serves as President of Atamyo's Strategic Committee. Collaboration on limb-girdle muscular dystrophy programs including ATA-200.

Scale indicators8 records

Recent moves10 records

Expansion highlights6 records

Genethon competitors and assessment

Company assessment

Broad incumbents

  • BioMarin Pharmaceutical: Rare-disease biotech with AAV gene therapy (Roctavian for hemophilia A) and broad rare-disease portfolio. Comparable in AAV modality and rare-disease commercial positioning.
  • AveXis (Novartis Gene Therapies): Novartis's gene therapy unit commercializing Zolgensma (onasemnogene abeparvovec) for spinal muscular atrophy — a neuromuscular AAV gene therapy directly comparable to Genethon's neuromuscular pipeline focus.
  • Pfizer: Global pharma with approved DMD gene therapy Beqvez (fordadistrogene movaparvovec). Comparable as a competing developer of AAV microdystrophin therapies for DMD and a major participant in rare-disease gene therapy.

Others

  • Yposkesi: CDMO spin-off of Genethon specialized in gene therapy manufacturing. Comparable as the bioproduction backbone serving Genethon's pipeline and external gene therapy clients.

Direct peers

  • Spark Therapeutics: AAV-based gene therapy developer (Luxturna) now a Roche subsidiary and co-founder of the GenoTher biocluster with Genethon. Directly comparable as an AAV gene therapy company targeting rare monogenic diseases.
  • Bluebird Bio: Gene therapy company developing lentiviral vector therapies for rare genetic diseases (sickle cell, beta-thalassemia, cerebral adrenoleukodystrophy). Comparable modality and rare-disease focus to Genethon's lentiviral and AAV programs.
  • AskBio: AAV gene therapy developer and Bayer subsidiary — Genethon's licensing partner for the Pompe disease GAA transgene. Comparable in AAV modality and rare-disease pipeline focus.
  • Sarepta Therapeutics: Approved Elevidys (delandistrogene moxeparvovec) for Duchenne muscular dystrophy — the most direct competitor to Genethon's GNT0004 in the AAV microdystrophin space, with shared indication and modality.
  • uniQure: AAV gene therapy company targeting rare diseases (hemophilia B with etranacogene dezaparvovec). Comparable to Genethon in modality, rare-disease focus, and European clinical pipeline.

Emerging players

  • Atamyo Therapeutics: Biotech spin-off from Genethon focused on gene therapy for limb-girdle muscular dystrophies (ATA-200, ATA-100). Comparable as a clinical-stage AAV gene therapy company operating inside the AFM-Téléthon ecosystem.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

Genethon social profiles

Digital presence

Genethon compliance and trust

Trust signal

Compliance1 record

Genethon financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Genethon leadership team

Management profile

Number of profiles

Profiles12 records

Genethon subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Genethon funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Genethon M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Genethon

What does Genethon do?

Genethon is a nonprofit French biotech research laboratory that develops gene therapies for rare genetic diseases, leveraging AAV vectors, CRISPR/Cas9 gene editing, and lentiviral platforms. It operates a pipeline of 15 gene therapy candidates covering Duchenne muscular dystrophy, Crigler-Najjar syndrome, limb-girdle muscular dystrophies, sickle cell disease, and other monogenic conditions, with its lead candidate GNT0004 in pivotal Phase III clinical trials. The organization also provides certified DNA banking, imaging cytometry services, and licenses proprietary gene therapy technologies to commercial partners.

Is Genethon a public or private company?

Genethon is a private company. It is classified as nonprofit foundation owned and is currently operating.

When was Genethon founded?

Genethon was founded in 1990. It employs 251 to 500 people.

Where is Genethon based?

Genethon is headquartered in Évry, France, in the Europe region.

How does Genethon make money?

Three revenue lines are on record. Nonprofit Research Funding and Charitable Donations are the primary driver. The others are licensing Royalties and Technology Transfer and gene Therapy Clinical Development Services.

Who are Genethon's main competitors?

Broad incumbents on record are BioMarin Pharmaceutical, AveXis (Novartis Gene Therapies) and Pfizer. Yposkesi is listed as an others. Direct peers are Spark Therapeutics, Bluebird Bio, AskBio, Sarepta Therapeutics and uniQure. Atamyo Therapeutics is listed as an emerging player.

Does Genethon have an API?

No public API is recorded for Genethon.

What industry is Genethon in?

Genethon's product category is Gene Therapy / Rare Disease Biopharmaceuticals. Its primary akta.pro industry code is HLAAACAE, Gene Therapy for Rare/Monogenic Diseases, with a secondary code of HLAAACAN, Gene Therapy CMC/Process Development Platforms (capsid engineering, producer cell lines, plasmids, upstream/downstream). Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireThe Speak Foundation Announces 2026 LGMD Scientific SummitThe Speak Foundation has announced the 2026 LGMD Scientific Summit, a virtual international scientific meeting scheduled for July 31, 2026, to convene researchers, clinicians, biotechnology leaders, regulators, and patient advocates to discuss advances in Limb-Girdle Muscular Dystrophy research and therapeutic development. The summit will feature sessions on gene therapy, regenerative medicine, biomarker qualification, and clinical trial innovation as multiple therapeutic programs advance through clinical development. BridgeBio Neuromuscular is serving as Platinum Sponsor and AskBio as Bronze Sponsor, with both companies also presenting alongside other biotech organizations including Sarepta Therapeutics, Genethon, MyoPax, Edgewise Therapeutics, and Cure Rare Disease.GlobeNewswireSK pharmteco und Genethon demonstrieren die Stärke des Produktionsstandorts Frankreich für das richtungsweisende DMD-GentherapieprogrammSK pharmteco and Genethon have announced details of their ongoing strategic manufacturing partnership for GNT-0004, an experimental AAV8 micro-dystrophin gene therapy for Duchenne Muscular Dystrophy, produced at SK pharmteco's Yposkesi facility in France. The collaboration has yielded 20 AAV8 micro-dystrophin batches at 400-liter scale, with 18 manufactured under current Good Manufacturing Practice standards, supporting Genethon's pivotal Phase III trial approved by the EMA and the UK's MHRA in 2025. Two-year follow-up data presented at the 2026 ASGCT annual meeting demonstrated sustained efficacy, clinically meaningful and durable improvements in muscle function, and a favorable safety profile in the first treated patients.GlobeNewswireSK pharmteco and Genethon Showcase French Manufacturing Strength Behind Pivotal DMD Gene Therapy ProgramSK pharmteco announced details of its ongoing strategic manufacturing partnership with Genethon to support the development and manufacturing of GNT-0004, an investigational AAV8-micro-dystrophin gene therapy for Duchenne Muscular Dystrophy. Through its French facility Yposkesi, SK pharmteco has produced 20 batches of the therapy at 400L scale, including 18 cGMP batches, supporting the drug's advancement through Phase I/II trials and the launch of a pivotal Phase III trial in Europe and the UK authorized by EMA and MHRA in 2025. Compelling two-year data presented at the 2026 ASGCT Annual Meeting demonstrated sustained efficacy and a favorable safety profile.BioSpaceSK pharmteco and Genethon Showcase French Manufacturing Strength Behind Pivotal DMD Gene Therapy ProgramSK pharmteco announced ongoing manufacturing support for Genethon's GNT-0004, an AAV8-micro-dystrophin gene therapy for Duchenne muscular dystrophy, including 20 batches at 400 L scale. The collaboration enabled the pivotal Phase III trial in Europe and the UK, expected to enroll 72 boys aged 6-10. SK pharmteco is also manufacturing additional clinical batches for the trial.AijournGenethon’s Recent Accomplishments Underscore the Progress of Genetic Medicine from Scientific Promise to Clinical RealityGenethon, a non-profit gene therapy R&D organization founded by AFM-Telethon, reported clinical trial updates including long-term efficacy and safety confirmation of GNT0004 for Duchenne muscular dystrophy and promising initial data for ATA-200 in limb-girdle muscular dystrophy R5. The organization also announced a collaboration with Ampersand Biosciences of Boston to engineer next-generation AAV capsids with superior tissue specificity for improved gene therapy targeting.Business Wire BlogGenethon’s Recent Accomplishments Underscore the Progress of Genetic Medicine from Scientific Promise to Clinical RealityGenethon, a non-profit gene therapy R&D organization based in France, reported clinical trial updates including positive long-term efficacy and safety data for GNT0004 in Phase 3 Duchenne muscular dystrophy trials and promising initial data for ATA-200 in limb-girdle muscular dystrophy. The organization also announced a collaboration with Boston-based Ampersand Biosciences to engineer new AAV capsids with superior tissue specificity for gene therapies. CEO Frederic Revah noted that while genetic medicine has proven its therapeutic potential, significant challenges remain in ensuring broad patient access.FinancialContent Business PageGenethon’s Recent Accomplishments Underscore the Progress of Genetic Medicine from Scientific Promise to Clinical RealityGenethon, a non-profit gene therapy R&D organization founded by the French Muscular Dystrophy Association, reported clinical trial updates including long-term efficacy data for GNT0004 in Phase 3 Duchenne muscular dystrophy trials and promising initial patient data for ATA-200 in limb-girdle muscular dystrophy. The organization announced a collaboration with Ampersand Biosciences of Boston to engineer next-generation AAV capsids with superior tissue specificity for improved gene therapy targeting. Frederic Revah, Genethon's CEO, noted that while genetic medicine has proven its therapeutic potential, significant challenges remain in ensuring broad patient access.MorningstarGenethon’s Recent Accomplishments Underscore the Progress of Genetic Medicine from Scientific Promise to Clinical RealityGenethon, a non-profit gene therapy R&D organization, reported clinical trial updates for its Duchenne muscular dystrophy gene therapy and announced a collaboration with Ampersand Biosciences to engineer AAV capsids with superior tissue specificity. The company also highlighted promising data from its limb-girdle muscular dystrophy therapy and a basket clinical trial publication.PR NewswireGenethon and Ampersand Biomedicines announce partnership to design novel AAV vectors with enhanced tissue specificity for more effective and better tolerated gene therapiesGenethon and Ampersand Biomedicines announced an exclusive collaboration to engineer new AAV vectors with enhanced tissue specificity for gene therapy, leveraging AI-powered design technology. The partnership aims to develop safer and more effective gene therapies, initially focusing on skeletal muscle, and plans to expand to other tissues. This alliance combines Genethon's gene therapy expertise with Ampersand's precision targeting platform to improve therapeutic outcomes.BioSpaceGenethon and Ampersand Biomedicines announce partnership to design novel AAV vectors with enhanced tissue specificity for more effective and better tolerated gene therapiesGenethon and Ampersand Biomedicines announced an exclusive collaboration to engineer novel AAV capsids with superior tissue specificity. The partnership will use Ampersand's AND platform to integrate tissue-specific ligands onto AAV capsids, initially targeting skeletal muscle. The collaboration aims to develop safer, more effective gene therapies with lower doses and reduced immune responses.